Anand Lakhkar completed his medical training from India and specialized in family medicine. He completed his Ph.D. training in Pharmacology from New York Medical College, Valhalla, New York. His main research area of interest is in developing new therapies for treatment of Class III pulmonary hypertension. He is interested in developing drug therapies, which target inflammation, oxidative stress and vasoconstriction seen in the pulmonary vasculature in patients with Class III pulmonary hypertension. The research work he did for his Ph.D. thesis dissected out some of the signaling mechanisms by which Dehydroepiandrosterone (DHEA) reduced contraction, oxidative stress and inflammation in the pulmonary arteries. These findings can serve as a platform to develop more selective drugs with minimal side effects for the treatment of class III pulmonary hypertension.
Pulmonary hypertension; Oxidative stress; Cardiovascular pharmacology; Fluid therapy; Anti-epileptic drugs; Asthma; COPD; Nitric oxide signaling; Heart failure.